5 Written Questions
5 Matching Questions
- a Examination Procedures
- b Publishing of Patents and Patent Application Publications With Lengthy Sequence Listings
- c Replacement or Supplemental of Deposit
AFTER A PATENT HAS ISSUED
- d Requirements for Compliance, Statements Regarding New Matter, and Sanctions for Failure to Comply
- e Material Capable of Self-Replication
Biological material includes material that is capable of self-replication either directly or indirectly.
5 Multiple Choice Questions
- Rejections Based on Deposit Issue
- Nucleotide and/or Amino Acid Sequence Disclosures in Patent Disclosure in Patent Applications
- Replacement or Supplement of Deposit
IN A PENDING APPLICATION
- Requirement for Statement Regarding Content of Official and Computer Readable Copies of Sequence Listing
- The Deposit Rules
Where the invention involves a biological material and words alone cannot sufficiently describe how to make and use the invention in a reproducible manner, access to the biological material may be necessary for the satisfaction of the statutory requirements for patentability under 35 U.S.C. 112.
5 True/False Questions
2422.05 → Reference to Previously Filed Identical Computer Readable Form; Continuing or Dericatiove Applications; Request for Transfer of Computer Readable Form
2407 → Acceptable Depository
The depository must:
(i)Have a continuous existence;
(ii)Exist independent of the control of the depositor;
(iii)Possess the staff and facilities sufficient to examine the viability of a deposit and store the deposit in a manner which ensures that it is kept viable and uncontaminated;
(iv)Provide for sufficient safety measures to minimize the risk of losing biological material deposited with it;
(v)Be impartial and objective;
(vi)Furnish samples of the deposited material in an expeditious and proper manner; and
(vii)Promptly notify depositors of its inability to furnish samples, and the reasons why.
2434 → Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences
Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141.
applicants may petition pursuant to 37 CFR 1.181 for examination of additional nucleotide sequences by providing evidence that the different nucleotide sequences do not cover independent and distinct inventions.
2404.03 → Biological Material That Is Known and Readily Available to the Public
hat is the mininum number of seeds that must be deposited to be considered by the Office? → 2500